Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Supplement stakeholders criticize folic acid-cancer study

This article was originally published in The Tan Sheet

Executive Summary

A report analyzing the association of folic acid and vitamin B12 supplementation with increased cancer incidence contains numerous flaws, says the Council for Responsible Nutrition and the Natural Products Association. The Journal of the American Medical Association published the 1study Nov. 18, which looked at two Norwegian homocysteine-lowering trials of patients with ischemic heart disease. Researchers led by Marta Ebbing of Haukeland University in Bergen, Norway, found in the combined analysis of 6,837 patients that the study population had a 25 percent higher incidence of lung cancer than the general population of Norway, where there is no folic acid fortification. NPA's VP of Scientific and Regulatory Affairs Daniel Fabricant called the study "flawed" due to its lack of analysis into intervening factors, including patients' treatment with beta-blockers and statins. Andrew Shao, VP of scientific and regulatory affairs for CRN, said the conclusions are "inconsistent with the larger body of data" on folic acid's benefits and with the inverse relationship between folic acid fortification and lung cancer incidence in the U.S

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts